Stockscreener 앱 받기
7.69
3.92%
0.29
전일 마감가:
$7.40
열려 있는:
$7.41
하루 거래량:
34,241
Relative Volume:
0.32
시가총액:
$48.58M
수익:
$28.83M
순이익/손실:
$-13.34M
주가수익비율:
-5.0592
EPS:
-1.52
순현금흐름:
$-7.49M
1주 성능:
+16.87%
1개월 성능:
+13.42%
6개월 성능:
-33.13%
1년 성능:
+141.63%
1일 변동 폭
$7.41
$8.00
1주일 범위
$6.1896
$8.20
52주 변동 폭
$1.44
$36.00
Exicure Inc Stock (XCUR) Company Profile
명칭
Exicure Inc
전화
847-673-1707
주소
2430 N. HALSTED ST., CHICAGO, IL
XCUR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.738 | 850.40M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.50 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.58 | 112.39M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1545 | 322.34M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.36 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-12-18 | 개시 | BMO Capital Markets | Outperform |
| 2019-11-20 | 개시 | Guggenheim | Buy |
Exicure Inc 주식(XCUR)의 최신 뉴스
Momentum divergence signals in Exicure Inc. chartHigh Return Strategy with Low Risk - Newser
Multi asset correlation models including Exicure Inc.Predictive Short-Term Market Reversal Alerts - Newser
What risks could impact Exicure Inc. stock performanceSwing Trade Picks with High Potential - Newser
Why Exicure Inc. stock attracts strong analyst attentionROI Focused Watchlist with Trade Confidence - Newser
Exicure Inc. stock daily chart insightsSmart Stock Forecast Using AI Algorithms - Newser
Using data models to predict Exicure Inc. stock movementReal Time Screener for Growth Trades - Newser
Exicure Regains Nasdaq Compliance, Files Q1 2025 Form 10-Q - AInvest
Historical volatility pattern of Exicure Inc. visualizedFree Access to Real-Time Trade Insights - Newser
Exicure, Inc. shares fall 1.97% premarket after regaining compliance with Nasdaq listing rules. - AInvest
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements - BioSpace
Will Exicure Inc. outperform the marketFree Triple Return Setup with Risk Control - Newser
Exicure Regains Nasdaq Compliance as of July 2025 - TipRanks
Exicure Regains Nasdaq Compliance After Filing Required Periodic Reports. - AInvest
Exicure, Inc. shares fall 1.32% after-hours after regaining compliance with Nasdaq listing rules. - AInvest
Exicure Regains Nasdaq Compliance, Announces New Focus on Strategic Alternatives - AInvest
What Did We Discover About Insider Trading At Exicure Inc (NASDAQ: XCUR)? - stocksregister.com
How does Exicure Inc. compare to its industry peersExplosive market performance - Jammu Links News
Is it the right time to buy Exicure Inc. stockAchieve rapid portfolio appreciation today - Jammu Links News
When is Exicure Inc. stock expected to show significant growthConsistent triple returns - Jammu Links News
Exicure Inc. Stock Analysis and ForecastSuperior stock selection - Jammu Links News
Is Exicure Inc. stock overvalued or undervaluedGet alerts on high-potential market moves - Jammu Links News
Is Exicure Inc. a good long term investmentMaximize gains with strategic stock entries - Jammu Links News
Published on: 2025-08-03 12:31:07 - Jammu Links News
Exicure, Inc. (NASDAQ:XCUR) Short Interest Update - Defense World
Published on: 2025-08-03 09:06:10 - Jammu Links News
Why is Exicure Inc. stock attracting strong analyst attentionCapitalize on strategic market trends - Jammu Links News
How does Exicure Inc. generate profit in a changing economyPhenomenal capital appreciation - Jammu Links News
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Lelezard
Exicure's GPC-100: A Game-Changer in Stem Cell Mobilization with Near-Term Data Catalysts - AInvest
Custom strategy builders for tracking Exicure Inc.AI Triggered Buy Zone Forecast System - Newser
Exicure's GPC-100: A High-Stakes Gamble in Myeloma Stem Cell Mobilization - AInvest
Analyzing Exicure Inc. with multi timeframe chartsTechnical Setup and Return Forecast Engine - Newser
What institutional investors are buying Exicure Inc. stockChart Pattern Updates With High Returns - Jammu Links News
Stocks to Watch: Exicure, TTEC - MarketWatch
Exicure completes last patient in Phase 2 GPC-100 combo trial - TipRanks
Exicure stock surges after completing Phase 2 trial enrollment By Investing.com - Investing.com Nigeria
Exicure stock surges after completing Phase 2 trial enrollment - Investing.com
Revolutionary 45-Minute Stem Cell Treatment Completes Phase 2 Trial, Replacing Overnight Protocol - Stock Titan
Exicure Inc (XCUR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.10%
0.21%
자본화:
|
볼륨(24시간):